Abstract | BACKGROUND: Studies have shown that repeated post-prandial hyperglycemia may play an important role in the development of atherosclerosis by suppressing endothelial function. α- Glucosidase inhibitors (α-GIs), which reduce post-prandial hyperglycemia without stimulating insulin secretion, significantly reduce the risk of coronary artery disease (CAD), whereas glinides, which improve post-prandial hyperglycemia through post-prandial insulin secretion, do not appear to affect CAD. METHODS AND RESULTS: CONCLUSIONS: The ameliorating effect of α-GI on post-prandial hyperglycemia without stimulating insulin secretion may improve atherogenic dyslipidemia by reducing insulin resistance. These effects are associated with its beneficial impact on oxidative stress, consequently leading to an improvement in endothelial dysfunction.
|
Authors | Takahiro Sawada, Hideyuki Shiotani, Daisuke Terashita, Yoshinori Nagasawa, Su-Shiku Kim, Masanobu Koide, Mitsuhiro Yokoyama |
Journal | Circulation journal : official journal of the Japanese Circulation Society
(Circ J)
Vol. 78
Issue 1
Pg. 248-55
( 2014)
ISSN: 1347-4820 [Electronic] Japan |
PMID | 24225338
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Cyclohexanes
- Enzyme Inhibitors
- Glycoside Hydrolase Inhibitors
- Hypoglycemic Agents
- Lipids
- miglitol
- 1-Deoxynojirimycin
- Nateglinide
- Phenylalanine
|
Topics |
- 1-Deoxynojirimycin
(administration & dosage, analogs & derivatives)
- Aged
- Aged, 80 and over
- Coronary Artery Disease
(blood, drug therapy, pathology)
- Cyclohexanes
(administration & dosage)
- Diabetic Angiopathies
(blood, drug therapy, pathology)
- Dyslipidemias
(blood, drug therapy, pathology)
- Endothelium, Vascular
(metabolism, pathology)
- Enzyme Inhibitors
(administration & dosage)
- Female
- Glycoside Hydrolase Inhibitors
- Humans
- Hyperglycemia
(blood, drug therapy, pathology)
- Hypoglycemic Agents
(administration & dosage)
- Insulin Resistance
- Lipids
(blood)
- Male
- Middle Aged
- Nateglinide
- Phenylalanine
(administration & dosage, analogs & derivatives)
|